Prognostic significance of the lymphocyte-to-monocyte ratio in patients with metastatic colorectal cancer

Table 1 Patient characteristics

Age (yr)
Median (range)	64 (27-86)
Gender
Male	59
Female	45
Performance status
0	96
1	6
2	2
Location of primary tumor
Colon	60
Rectum	44
Histological type
Well, moderately	81
Poorly, mucinous	14
KRAS
Wild type	25
Mutant type	25
Unknown	54
Detection of unresectable tumor
Synchronous	62
Metachronous	42
Number of organs affected by metastasis
One organ	58
More than one organ	46
Resection of primary tumor
No	16
Yes	88
Regimen of first-line chemotherapy
FOLFOX	64
CapeOX	26
FOLFIRI	9
SOX	5
Molecular targeted therapy
No	28
Yes	76
Pre-treatment LMR (mean ± SD)	4.548 ± 2.314
Pre-treatment NLR (mean ± SD)	3.204 ± 2.284

FOLFOX: 5-fluorouracil + leucovorin + oxaliplatin; CapeOX: Capecitabine + oxaliplatin; FOLFIRI: 5-fluorouracil + leucovorin + irinotecan; SOX: S-1 + oxaliplatin; LMR: Lymphocyte to monocyte ratio; NLR: Neutrophil to lymphocyte ratio.